Pfizer is proud to announce the 2012 Advancing Research in Transplantation Science (ARTS) Awards: a competitive, independent, peer reviewed research award program.

As competition for research funding increases, the Pfizer ARTS award program underscores Pfizer’s commitment to supporting investigators with an interest in advancing their academic research.


The mission of the Pfizer ARTS award program is to support basic and clinical science through a competitive, independent peer-reviewed program that advances the understanding and medical knowledge of mTOR pathway inhibition in transplantation and related areas.


Basic science and clinical research continue to advance our knowledge and understanding of mTOR inhibition and its role in transplantation, immunity and inflammation. However, the clinical applicability of these findings is not always apparent and correlative studies may not be readily available.

The Pfizer ARTS award program is designed to support research in areas related to mTOR pathway inhibition, both mechanistic and clinical.

Pfizer is hopeful that the outcomes of this research program will contribute to the knowledge of mTOR pathway inhibition and its potential effect on improving patient health.

Areas of Research Focus

Pfizer will support clinical and basic science research exploring mTOR pathway inhibition in the following areas:

Available Awards

The 2012 Application is open to US investigators only. The selection of research proposals will be performed by an independent, external review committee comprised of academic clinicians/scientists who are experts in the field. Submitted applications should be for projects lasting no longer than two years in duration. Award funding is limited to $250,000 per award for the entirety of the project.

Review Committee Membership

To download a list of the committee membership, CLICK HERE.


Please see the FREQUENTLY ASKED QUESTIONS (FAQ) TAB for help, or contact the Pfizer ARTS award program Coordinator, via email: